Advances in the development of new tuberculosis drugs and treatment regimens (original) (raw)
Zumla, A., Raviglione, M., Hafner, R. & von Reyn, C. F. Tuberculosis. N. Engl. J. Med.368, 745–755 (2013). An important update of current concepts on the clinical, epidemiological and management aspects of tuberculosis. ArticleCASPubMed Google Scholar
Grange, J. M. in Tuberculosis: A Comprehensive Clinical Reference (eds Schaaf, S. & Zumla, A. I.) 44–59 (Saunders, 2009). Book Google Scholar
Dye, C., Scheele, S., Dolin, P., Pathania, V. & Raviglione, M. C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA282, 677–686 (1999). ArticleCASPubMed Google Scholar
Diel, R. et al. Old ideas to innovate TB control: preventive treatment to achieve elimination. Eur. Respir. J. 8 Feb 2013 (10.1183/09031936.00205512).
Raviglione, M. et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet379, 1902–1913 (2012). ArticlePubMed Google Scholar
World Health Organization. Global Tuberculosis Report 2012 (WHO, 2012).
European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis Surveillance and Monitoring in Europe (European Centre for Disease Prevention and Control, 2012).
Hill, A. N., Becerra, J. & Castro, K. G. Modelling tuberculosis trends in the USA. Epidemiol. Infect.140, 1862–1872 (2012). ArticleCASPubMed Google Scholar
Cohen, J. Infectious disease. Approval of novel TB drug celebrated — with restraint. Science339, 130 (2013). ArticleCASPubMed Google Scholar
World Health Organization. Treatment of Tuberculosis Guidelines 4th edn (WHO, 2010).
Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC) 2nd edn (Tuberculosis Coalition for Technical Assistance, 2009)
Johnson, J. L. et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am. J. Respir. Crit. Care Med.180, 558–563 (2009). ArticlePubMedPubMed Central Google Scholar
Lienhardt, C. et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the study C randomized controlled trial. JAMA305, 1415–1423 (2011). ArticleCASPubMed Google Scholar
Dooley, K. E. et al. Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. Clin. Infect. Dis.55, 572–581 (2012). ArticleCASPubMedPubMed Central Google Scholar
Falzon, D. et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur. Respir. J.38, 516–528 (2011). ArticleCASPubMed Google Scholar
Lawn, S. D. & Zumla, A. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect. Dis.13, 349–361 (2013). A critical review of the Xpert MTB/RIF assay and the advantages and limitations of its utility in clinical practice. ArticleCASPubMedPubMed Central Google Scholar
Weyer, K. et al. Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert®MTB/RIF. Eur. Respir. J. 22 Nov 2012 (10.1183/09031936.00157212).
Gandhi, N. R. et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet368, 1575–1580 (2006). ArticlePubMed Google Scholar
Dheda, K. et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet375, 1798–1807 (2010). ArticlePubMed Google Scholar
Jacobson, K. R., Tierney, D. B., Jeon, C. Y., Mitnick, C. D. & Murray, M. B. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin. Infect. Dis.51, 6–14 (2010). ArticlePubMed Google Scholar
Migliori, G. B. et al. Drug resistance beyond XDR-TB: results from a large individual patient data meta-analysis. Eur. Respir. J. 11 Oct 2012 (10.1183/09031936.00136312).
Udwadia, Z. F., Amale, R. A., Ajbani, K. K. & Rodrigues, C. Totally drug-resistant tuberculosis in India. Clin. Infect. Dis.54, 579–581 (2012). ArticlePubMed Google Scholar
World Health Organization. “Totally Drug-Resistant TB”: a WHO consultation on the diagnostic definition and treatment options. World Health Organization[online], (2012).
Cole, S. T. & Riccardi, G. New tuberculosis drugs on the horizon. Curr. Opin. Microbiol.14, 570–576 (2011). ArticleCASPubMed Google Scholar
Koul, A., Arnoult, E., Lounis, N., Guillemont, J. & Andries, K. The challenge of new drug discovery for tuberculosis. Nature469, 483–490 (2011). ArticleCASPubMed Google Scholar
Global-Alliance for TB Drug Development. Tuberculosis. Scientific blueprint for tuberculosis drug development. Tuberculosis (Edinb.)81, (Suppl. 1), 1–52 (2001).
Barry, C. E. et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nature Rev. Microbiol.7, 845–855 (2009). ArticleCAS Google Scholar
Jindani, A., Doré, C. J. & Mitchison, D. A. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med.167, 1348–1354 (2003). ArticlePubMed Google Scholar
Donald, P. R. & Diacon, A. H. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis (Edinb.)88, (Suppl. 1), 75–83 (2008). Article Google Scholar
Nuermberger, E. L. et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit. Care Med.169, 421–426 (2004). ArticlePubMed Google Scholar
Ma, Z., Lienhardt, C., McIlleron, H., Nunn, A. J. & Wang, X. Global tuberculosis drug development pipeline: the need and the reality. Lancet375, 2100–2109 (2010). ArticlePubMed Google Scholar
Rosenthal, I. M. et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med.4, e344 (2007). ArticleCASPubMedPubMed Central Google Scholar
Sterling, T. R. et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N. Engl. J. Med.365, 2155–2166 (2011). ArticleCASPubMed Google Scholar
Diacon, A. H. et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother.51, 2994–2996 (2007). ArticleCASPubMedPubMed Central Google Scholar
van Ingen, J. et al. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin. Infect. Dis.52, e194–e199 (2011). ArticleCASPubMed Google Scholar
Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science307, 223–227 (2005). A landmark paper describing the discovery and development of bedaquiline and the validation of a novel yet ubiquitous new drug target for TB. ArticleCASPubMed Google Scholar
Dey, T. et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J. Antimicrob. Chemother.68, 284–293 (2013). ArticleCASPubMed Google Scholar
Van Deun, A. et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med.182, 684–692 (2010). An observational “Bangladesh” standardized regimen study, with a duration of 9–12 months, that included gatifloxacin, ethambutol, pyrazinamide and clofazimine throughout, supplemented by kanamycin, prothionamide and isoniazid. During an intensive phase of 4 months this regimen achieved <1% failure and ∼90% relapse-free cure. ArticlePubMed Google Scholar
Verma, R. K. et al. Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob. Agents Chemother.57, 1050–1052 (2013). ArticleCASPubMedPubMed Central Google Scholar
Zhang, M. et al. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob. Agents Chemother.56, 5782–5789 (2012). ArticleCASPubMedPubMed Central Google Scholar
Ashtekar, D. R. et al. Oxazolidinone, a new class of synthetic antituberculosis agent: in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn. Microbiol. Infect. Dis.14, 465–471 (1991). ArticleCASPubMed Google Scholar
Fortun, J. et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother.56, 180–185 (2005). ArticleCASPubMed Google Scholar
Lee, M. et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med.367, 1508–1518 (2012). A demonstration that linezolid, a drug with poor EBA, can improve the prognosis of patients with XDR-TB, thus providing hope that next-generation oxazolidinones may be even better. ArticleCASPubMed Google Scholar
Sotgiu, G. et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur. Respir. J.40, 1430–1442 (2012). ArticleCASPubMed Google Scholar
Wallis, R. S. et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob. Agents Chemother.55, 567–574 (2010). ArticleCASPubMedPubMed Central Google Scholar
Wallis, R. S. et al. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J. Infect. Dis.202, 745–751 (2010). ArticleCASPubMed Google Scholar
Wallis, R. S. et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS ONE7, e30479 (2012). ArticleCASPubMedPubMed Central Google Scholar
Reele, S. et al. A 14-day multiple ascending dose study: AZD5847 is well tolerated at predicted exposure for treatment of tuberculosis (TB) (Abstract A1-1735). 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy[online], (2011). Google Scholar
Hugonnet, J. E. et al. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science323, 1215–1218 (2009). ArticleCASPubMedPubMed Central Google Scholar
Dauby, N., Muylle, I., Mouchet, F., Sergysels, R. & Payen, M. C. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Pediatr. Infect. Dis. J.30, 812–813 (2011). ArticlePubMed Google Scholar
De Lorenzo, S. et al. Efficacy and safety of meropenem/clavunate added to linezolid containing regimens in the treatment of M/XDR-TB. Eur. Respir. J. 20 Sept 2012 (10.1183/09031936.00124312).
Koul, A. et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nature Chem. Biol.3, 323–324 (2007). ArticleCAS Google Scholar
Haagsma, A. C. et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob. Agents Chemother.53, 1290–1292 (2009). ArticleCASPubMed Google Scholar
Huitric, E. et al. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob. Agents Chemother.54, 1022–1028 (2009). ArticleCASPubMedPubMed Central Google Scholar
Biukovic, G. et al. Variations of subunit ε of the Mycobacterium tuberculosis F1F0 ATP synthase and a novel model for mechanism of action of the TB drug TMC207. Antimicrob. Agents Chemother.57, 168–176 (2013). ArticleCASPubMedPubMed Central Google Scholar
Koul, A. et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem.283, 25273–25280 (2008). ArticleCASPubMed Google Scholar
Rao, S. P., Alonso, S., Rand, L., Dick, T. & Pethe, K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA105, 11945–11950 (2008). ArticlePubMedPubMed Central Google Scholar
Diacon, A. H. et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med.360, 2397–2405 (2009). An important publication documenting the considerable impact of bedaquiline on the prognosis of patients with MDR-TB and the value of testing new drugs in MDR cohorts. ArticleCASPubMed Google Scholar
Veziris, N. et al. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am. J. Respir. Crit. Care Med.179, 75–79 (2009). ArticleCASPubMed Google Scholar
Lounis, N. et al. Prevention of drug carryover effects in studies assessing antimycobacterial efficacy of TMC207. J. Clin. Microbiol.46, 2212–2215 (2008). ArticleCASPubMedPubMed Central Google Scholar
Lin, P. L. et al. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc. Natl Acad. Sci. USA109, 14188–14193 (2012). ArticlePubMedPubMed Central Google Scholar
Stover, C. K. et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature405, 962–966 (2000). ArticleCASPubMed Google Scholar
Matsumoto, M. et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med.3, e466 (2006). ArticleCASPubMedPubMed Central Google Scholar
Manjunatha, U. H. et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA103, 431–436 (2006). ArticleCASPubMed Google Scholar
Singh, R. et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science322, 1392–1395 (2008). An important publication documenting a novelM. tuberculosiskilling mechanism mediated by PA-824 (and later by delaminid) that provides proof of concept for developing novel NO donor drugs for treating TB. ArticleCASPubMedPubMed Central Google Scholar
Hurdle, J. G. et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J. Antimicrob. Chemother.62, 1037–1045 (2008). ArticleCASPubMedPubMed Central Google Scholar
Manjunatha, U., Boshoff, H. I. & Barry, C. E. The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun. Integr. Biol.2, 215–218 (2009). ArticleCASPubMedPubMed Central Google Scholar
Diacon, A. et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824; Antimicrob. Agents Chemother.56, 3027–3031 (2012). ArticleCASPubMedPubMed Central Google Scholar
Diacon, A. H. et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet380, 986–993 (2012). A seminal study describing how the use of EBA with combination therapies has the potential to reduce the time needed for developing new multidrug regimens. ArticleCASPubMed Google Scholar
Diacon, A. H. et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int. J. Tuberc. Lung Dis.15, 949–954 (2011). ArticleCASPubMed Google Scholar
Gler, M. T. et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med.366, 2151–2160 (2012). An encouraging publication demonstrating that delamanid could enhance treatment options for patients with MDR-TB. ArticleCASPubMed Google Scholar
Skripconoka, V. et al. Delamanid improves outcomes and reduces mortality for multidrug-resistant tuberculosis. Eur. Respir. J. 27 Sept 2012 (10.1183/09031936.00125812).
Lee, R. E. et al. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J. Comb. Chem.5, 172–187 (2003). ArticleCASPubMed Google Scholar
Tahlan, K. et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother.56, 1797–1809 (2012). ArticleCASPubMedPubMed Central Google Scholar
Reddy, V. M., Einck, L., Andries, K. & Nacy, C. A. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob. Agents Chemother.54, 2840–2846 (2010). ArticleCASPubMedPubMed Central Google Scholar
Grzegorzewicz, A. E. et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nature Chem. Biol.8, 334–341 (2012). ArticleCAS Google Scholar
La Rosa, V. et al. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob. Agents Chemother.56, 324–331 (2012). ArticleCASPubMedPubMed Central Google Scholar
Stanley, S. A. et al. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem. Biol.7, 1377–1384 (2012). ArticleCASPubMedPubMed Central Google Scholar
Makarov, V. et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science324, 801–804 (2009). A landmark paper presenting both a new chemical entity and a novel drug target for TB therapy. ArticleCASPubMedPubMed Central Google Scholar
Pasca, M. R. et al. Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. Antimicrob. Agents Chemother.54, 1616–1618 (2010). ArticleCASPubMedPubMed Central Google Scholar
Lechartier, B., Hartkoorn, R. C. & Cole, S. T. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother.56, 5790–5793 (2012). ArticleCASPubMedPubMed Central Google Scholar
Neres, J. et al. Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci. Transl. Med.4, 150ra121 (2012). ArticleCASPubMedPubMed Central Google Scholar
Trefzer, C. et al. Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-d-ribose 2′-epimerase DprE1 of Mycobacterium tuberculosis. J. Am. Chem. Soc.132, 13663–13665 (2010). ArticleCASPubMed Google Scholar
Trefzer, C. et al. Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-d-ribofuranose 2′-oxidase DprE1. J. Am. Chem. Soc.134, 912–915 (2012). ArticleCASPubMed Google Scholar
Christophe, T. et al. High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog.5, e1000645 (2009). ArticleCASPubMedPubMed Central Google Scholar
Magnet, S. et al. Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis (Edinb.)90, 354–360 (2010). ArticleCAS Google Scholar
Nunn, A. J., Phillips, P. P. & Mitchison, D. A. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int. J. Tuberc. Lung Dis.14, 241–242 (2010). CASPubMed Google Scholar
Merle, C. S. et al. A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the gatifloxacin for TB (OFLOTUB) project. Trials13, 61 (2012). ArticleCASPubMedPubMed Central Google Scholar
Phillips, P. P. et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J. Infect. Dis.205, (Suppl. 2), 250–257 (2012). Article Google Scholar
Wallis, R. et al. Tuberculosis biomarkers discovery: developments, needs and challenges. Lancet Infect. Dis.13, 362–372 (2013). An important review of the latest information on progress on TB biomarkers development. ArticlePubMed Google Scholar
Horne, D. J. et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect. Dis.10, 387–394 (2010). ArticlePubMedPubMed Central Google Scholar
Walzl, G., Ronacher, K., Hanekom, W., Scriba, T. J. & Zumla, A. Immunological biomarkers of tuberculosis. Nature Rev. Immunol.11, 343–354 (2011). ArticleCAS Google Scholar
McNerney, R. et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J. Infect. Dis.205 (Suppl. 2), 147–158 (2012). Article Google Scholar
Nahid, P. et al. CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am. J. Respir. Crit. Care Med.184, 972–979 (2011). ArticlePubMedPubMed Central Google Scholar
Skrahina, A. et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur. Respir. J.39, 1425–1431 (2012). ArticlePubMed Google Scholar
Abubakar, I. et al. Drug resistant tuberculosis: time for visionary political leadership. Lancet Infect. Dis. 24 Mar 2013 (10.1016/S1473-3099(13)70030-6).
Schatz, A., Bugie, E. & Waksman, S. A. Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Proc. Soc. Exp. Biol. Med.55, 66–69 (1944). ArticleCAS Google Scholar
Marshall, G. Streptomycin in the treatment of pulmonary tuberculosis. A Medical Research Council investigation. BMJ1, 382–386 (1949). Article Google Scholar
American Thoracic Society. Treatment of tuberculosis. Am. J. Respir. Crit. Care Med.167, 603–662 (2003).
Gengiah, T. N., Gray, A. L., Naidoo, K. & Karim, Q. A. Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opin. Drug Saf.10, 559–574 (2011). ArticleCASPubMedPubMed Central Google Scholar
Blanc, F. X. et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N. Engl. J. Med.365, 1471–1481 (2011). ArticleCASPubMedPubMed Central Google Scholar
Subbian, S. et al. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog.7, e1002262 (2011). ArticleCASPubMedPubMed Central Google Scholar
Tobin, D. M. et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell148, 434–446 (2012). ArticleCASPubMedPubMed Central Google Scholar
Skerry, C., Harper, J., Klunk, M., Bishai, W. R. & Jain, S. K. Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas. PLoS ONE7, e39680 (2012). ArticleCASPubMedPubMed Central Google Scholar
Napier, R. J. et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe10, 475–485 (2012). ArticleCAS Google Scholar
Ivanyi, I. & Zumla, A. Non-steroidal anti-inflammatory drugs for adjunctive tuberculosis treatment. J. Infect. Dis. 5 Apr 2013 (10.1093/infdis/jit153).
Amaral, L., Martins, M. & Viveiros, M. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J. Antimicrob. Chemother.59, 1237–1246 (2007). ArticleCASPubMed Google Scholar
Lim, L. E. et al. Anthelmintic avermectins kill M. tuberculosis, including multidrug-resistant clinical strains. Antimicrob. Agents Chemother.57, 1040–1046 (2013). ArticleCASPubMedPubMed Central Google Scholar
Maiga, M. et al. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. PLoS ONE7, e30749 (2012). ArticleCASPubMedPubMed Central Google Scholar
Uhlin, M., Andersson, J., Zumla, A. & Maeurer, M. Adjunct immunotherapies for tuberculosis. J. Infect. Dis.205 (Suppl. 2), 325–334 (2012). ArticleCAS Google Scholar
Bruns, H. et al. Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages. J. Immunol.189, 4069–4078 (2012). ArticleCASPubMed Google Scholar
Kuijl, C. et al. Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature.450, 725–730 (2007). ArticleCASPubMed Google Scholar
Boshoff, H. I. & Barry, C. E. 3rd. Tuberculosis — metabolism and respiration in the absence of growth. Nature Rev. Microbiol.3, 70–80 (2005). ArticleCAS Google Scholar
Pym, A. S. & Cole, S. T. in Bacterial Resistance to Antimicrobials 2nd Edn (eds Wax, R. G., Lewis, K., Salyers, A. A. & Taber, H.) 313–342 (CRC, 2008). Google Scholar
Chakraborty, S., Gruber, T., Barry, C. E. 3rd, Boshoff, H. I. & Rhee, K. Y. _Para_-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science339, 88–91 (2013). ArticleCASPubMed Google Scholar
Sirgel, F. A. et al. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J. Antimicrob. Chemother.67, 1088–1093 (2012). ArticleCASPubMed Google Scholar
Sirgel, F. A. et al. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microb. Drug Resist.18, 193–197 (2012). ArticleCASPubMed Google Scholar
Salian, S. et al. Structure–activity relationships among the kanamycin aminoglycosides: role of ring I hydroxyl and amino groups. Antimicrob. Agents Chemother.56, 6104–6108 (2012). ArticleCASPubMedPubMed Central Google Scholar
Global Alliance for TB Drug Development. Cycloserine. Tuberculosis (Edinb.)88, 100–101 (2008).
Bruning, J. B., Murillo, A. C., Chacon, O., Barletta, R. G. & Sacchettini, J. C. Structure of the Mycobacterium tuberculosis d-alanine:d-alanine ligase, a target of the antituberculosis drug d-cycloserine. Antimicrob. Agents Chemother.55, 291–301 (2010). ArticleCASPubMedPubMed Central Google Scholar
Benator, D. et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet360, 528–534 (2002). ArticlePubMed Google Scholar
Steingart, K. R., et al. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int. J. Tuber. Lung Dis.15, 305–316 (2011). CAS Google Scholar
Batt, S. M., et al. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc. Natl Acad. Sci. USA109, 11354–11359 (2012). ArticlePubMedPubMed Central Google Scholar